| Literature DB >> 28843001 |
Kevin Tran1, Chandrasekhar Gurramkonda1, Merideth A Cooper2, Manohar Pilli1, Joseph E Taris2, Nicholas Selock1, Tzu-Chiang Han2, Michael Tolosa1, Adil Zuber1, Chariz Peñalber-Johnstone1, Christina Dinkins1, Niloufar Pezeshk1, Yordan Kostov1, Douglas D Frey1, Leah Tolosa1, David W Wood2, Govind Rao1.
Abstract
The use of cell-free systems to produce recombinant proteins has grown rapidly over the past decade. In particular, cell-free protein synthesis (CFPS) systems based on mammalian cells provide alternative methods for the production of many proteins, including those that contain disulfide bonds, glycosylation, and complex structures such as monoclonal antibodies. In the present study, we show robust production of turbo green fluorescent protein (tGFP) and streptokinase in a cell-free system using instrumented mini-bioreactors for highly reproducible protein production. We achieved recombinant protein production (∼600 μg/ml of tGFP and 500 μg/ml streptokinase) in 2.5 hr of expression time, comparable to previously reported yields for cell-free protein expression. Also, we demonstrate the use of two different affinity tags for product capture and compare those to a tag-free self-cleaving intein capture technology. The intein purification method provided a product recovery of 86%, compared with 52% for conventionally tagged proteins, while resulting in a 30% increase in total units of activity of purified recombinant streptokinase compared with conventionally tagged proteins. These promising beneficial features combined with the intein technology makes feasible the development of dose-level production of therapeutic proteins at the point-of-care.Entities:
Keywords: cell-free in vitro translation; green fluorescent protein; intein technology; mini-bioreactors
Mesh:
Substances:
Year: 2017 PMID: 28843001 DOI: 10.1002/bit.26439
Source DB: PubMed Journal: Biotechnol Bioeng ISSN: 0006-3592 Impact factor: 4.530